$FIL-USD

RedStone: Oracle infrastructure launches on Filecoin mainnet - 22 Oct 2026

RedStone launched its oracle data infrastructure on Filecoin mainnet, starting with a FIL/USD price feed. The feed updates every 0.5% price move or at least every four hours, providing FIL's onchain dollar price to Filecoin Virtual Machine smart contracts.

Original reporting
Published Oct 22, 2026, 8:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 8:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
RedStone: Oracle infrastructure launches on Filecoin mainnet - 22 Oct 2026 — source image
Decision brief

The 30-second read

$FIL-USDBullishLow
01

Why it matters

The launch introduces a new price feed, potentially improving market confidence in FIL pricing.

02

Market read

Adds a data layer to Filecoin, modestly supportive for FIL traders.

03

What to watch

Potential competition from other oracle providers could dilute impact.

Relevance 5/10Novelty 6/10Timing: immediate

Background

RedStone is a provider of real‑world data feeds for blockchain applications.

Company-level read

Ticker impact

$FIL-USDBullishMedium confidence
Context

RedStone launched an oracle feed on Filecoin mainnet providing on‑chain FIL/USD price updates.

Expected impact

likely modest upside as traders gain reliable price data

Evidence & confidence

First‑time oracle integration adds utility, but scale is limited.

Market effects

enhances data infrastructure for decentralized finance on Filecoin

primarily affects crypto markets globally

limited to blockchain and oracle ecosystem participants

Counterpoint

Oracle addition may not drive significant FIL price movement if adoption is slow.

Key entities

  • RedStone

    Oracle data provider launching on Filecoin.

  • Filecoin

    Decentralized storage network whose native token is FIL.

Related articles

$VBIOMed

Valion Bio, Inc.: Valion Bio Advancing Entolimod into U.S. Government-Funded Therapeutic Efficacy Study Following Positive Safety Results

Valion Bio (VBIO) announced that the National Institute of Allergy and Infectious Diseases (NIAID) will fund a study to evaluate the efficacy of Entolimod, its lead drug candidate, in treating gastrointestinal acute radiation syndrome (GI-ARS). The study, conducted by the Armed Forces Radiobiology Research Institute (AFRRI), follows positive safety results and aims to assess survival rates and tissue recovery post-radiation. Top-line results are expected in early December.

$TMLow

Toyota and Waymo advance autonomous driving collaboration

Toyota and Waymo are advancing their autonomous driving collaboration, testing a fleet of Toyota bZ4X vehicles in Japan in 2027, with plans to expand to the UK and other markets. The partnership aims to scale safety-validated Level 4 autonomous vehicles, with Toyota manufacturing the vehicles in Japan. Both companies highlight the potential for reducing human-error accidents and improving road safety. Waymo claims its technology is up to 20x safer than human drivers in areas it operates.

$PULMMedAI 8/10

Eos reports early rat study data for aging drug candidate

Eos SENOLYTIX reported interim data from a rat study of its aging drug candidate PTC-2105, showing improved motor performance and reduced fat mass. The 32-week study involves 268 rats, with the oldest cohort showing positive results. Eos plans FDA submission and human trials in 2027. The company is merging with Pulmatrix Inc. (PULM), expected to close in Q4 2026.